Senti Bio posts upbeat initial data from a phase I study on SENTI-202 for the treatment of relapsed/refractory hematologic malignancies. Stock soars.

Senti Bio (SNTI)science reported positive initial clinical data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural kille ...

HIV research progresses toward a cure, with promising gene therapy and immunotherapy strategies. Continued focus is essential ...

When five and a half feet of flooding waters filled the basement of Misuta Chow’s after a water main break, it was considered ...

In the USA, children with sickle cell disease increasingly survive into adulthood, leading to an expanding population of ...

So how could I narrow that all down to just 10 picks? With such a limited number, the criteria are heightened: I’m talking ...

Some of Greater Boston’s most exciting urban restaurants aren’t in Boston — they’re in Quincy, a city entrepreneurs are finding "very conducive to small businesses." ...

An author and expert on wellness visited a massive school in a country renowned for having the world’s best life expectancy ...

Sometimes, on an autumn day somewhere in eastern Europe, it can be difficult to tell precisely which century has fallen under ...

Liquid Biopsy MarketThe global liquid biopsy market is on a trajectory of unprecedented growth, with revenues projected to soar from USD 1,538.3 million in 2023 to an astounding USD 10,938.6 million ...